Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

RBC Capital Maintains Outperform on 89bio, Lowers Price Target to $32

Author: Benzinga Newsdesk | May 12, 2022 07:19am

RBC Capital analyst Brian Abrahams maintains 89bio (NASDAQ:ETNB) with a Outperform and lowers the price target from $35 to $32.

Posted In: ETNB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist